Survival Benefits with Keytruda and Padcev in Advanced Urothelial Cancer
Patients with previously untreated locally advanced or metastatic urothelial carcinoma experienced favorable progression-free survival, overall survival and objective response rates when treated with Padcev and Keytruda versus chemotherapy.
United States Padcev Keytruda Michiels Van Michiel Van Der Heijden Research Group Netherlands Cancer Institute Drug Administration
Source: curetoday.com